Intech Biopharm (Taiwan) Investor Sentiment

6461 Stock  TWD 28.00  0.65  2.27%   
Slightly above 62% of Intech Biopharm's investor base is looking to short. The analysis of current outlook of investing in Intech Biopharm suggests that many traders are alarmed regarding Intech Biopharm's prospects. Intech Biopharm's investing sentiment can be driven by a variety of factors including economic data, Intech Biopharm's earnings reports, geopolitical events, and overall market trends.
Intech Biopharm stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Intech daily returns and investor perception about the current price of Intech Biopharm as well as its diversification or hedging effects on your existing portfolios.
  
2 days ago at news.google.com         
61,679 Shares in GrafTech International Ltd. Purchased by Intech Investment Management LLC - Defense...
Google News at Macroaxis
3 days ago at news.google.com         
Quantbot Technologies LP Purchases Shares of 15,425 Xeris Biopharma Holdings, Inc. - Defense World
Google News at Macroaxis
over a week ago at news.google.com         
Intech Investment Management LLC Takes 1.32 Million Position in Krystal Biotech, Inc. - MarketBeat
Google News at Macroaxis
over two weeks ago at news.google.com         
Intech Investment Management LLC Buys 33,542 Shares of Halozyme Therapeutics, Inc. - MarketBeat
Google News at Macroaxis
over two weeks ago at news.google.com         
Intech Investment Management LLC Has 8.24 Million Stock Position in Vertex Pharmaceuticals Incorpora...
Google News at Macroaxis
over three weeks ago at news.google.com         
Xeris Biopharma Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
Google News at Macroaxis
over two months ago at news.google.com         
Intech Investment Management LLC Invests 241,000 in Lindsay Co. - Defense World
Google News at Macroaxis
over two months ago at news.google.com         
Intech Investment Management LLC Invests 435,000 in Cinemark Holdings, Inc. - MarketBeat
Google News at Macroaxis
over two months ago at news.google.com         
Intech Investment Management LLC Makes New 1.19 Million Investment in Halozyme Therapeutics, Inc. - ...
Google News at Macroaxis
over three months ago at news.google.com         
Mereo BioPharma Groups Overweight Rating Reiterated at Cantor Fitzgerald - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Vertex Pharmaceuticals Incorporated Position Boosted by Intech Investment Management LLC - MarketBea...
Google News at Macroaxis
over three months ago at news.google.com         
Arbutus Biopharma Co. Shares Acquired by BNP Paribas Financial Markets - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
ArriVent BioPharma, Inc.s Lock-Up Period Will Expire on July 24th - Defense World
Google News at Macroaxis
over three months ago at news.google.com         
Theravance Biopharma Upgraded by StockNews.com to Buy - American Banking and Market News
Google News at Macroaxis
over three months ago at news.google.com         
Avid Bioservices Shares Cross Above 200-Day Moving Average of 7.25 - American Banking and Market New...
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Intech Biopharm that are available to investors today. That information is available publicly through Intech media outlets and privately through word of mouth or via Intech internal channels. However, regardless of the origin, that massive amount of Intech data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Intech Biopharm news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Intech Biopharm relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Intech Biopharm's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Intech Biopharm alpha.

Intech Biopharm Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Additional Tools for Intech Stock Analysis

When running Intech Biopharm's price analysis, check to measure Intech Biopharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intech Biopharm is operating at the current time. Most of Intech Biopharm's value examination focuses on studying past and present price action to predict the probability of Intech Biopharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intech Biopharm's price. Additionally, you may evaluate how the addition of Intech Biopharm to your portfolios can decrease your overall portfolio volatility.